BLAINVILLE, QC, September 14, 2018 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.
The poster titled Adherence, Persistence and Healthcare Costs Associated with Ospemifene Compared with Local Estrogen Therapy among Commercially Insured Women in the United States, will be presented during the Poster Session on October 4, 2018, from 6:00 to 7:00 p.m. PST.
This poster will include data related to the adherence and healthcare utilization and costs of ospemifene in menopausal women with dyspareunia, a symptom of vulvovaginal atrophy (VVA), a part of the genitourinary syndrome of menopause (GSM).
“We look forward to sharing real world VVA treatment data on the adherence and healthcare utilization of ospemifene compared to local estrogen therapies for the treatment of dyspareunia, a symptom of VVA,” said Graziella Soulban, Senior Director of Medical Affairs at Duchesnay. “It is important to better understand adherence because it is a potential barrier affecting VVA symptom improvement in the treatment of post-menopausal women.”
Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay also commercializes a broad portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. For more information, visit www.DuchesnayUSA.com.